Rosetta Genomics and Max Planck Society Enter Microrna Licensing Agreement

    NORTH BRUNSWICK, New Jersey, July 27 /PRNewswire/ --
     - Deal Gives Rosetta Genomics Access to Potentially Hundreds of Human
 Proprietary Microrna Sequences With Possible Applications in the
 Development of a Wide Range of Diagnostic Tools For a Variety of Diseases
     Rosetta Genomics today announced that it has secured the rights to
 patents covering potentially hundreds of human microRNA sequences in
 diagnostic applications, through a co-exclusive license agreement. The
 agreement was signed with Garching Innovation, the technology transfer
 agency of the Max Planck Society, one of the leading scientific research
 organizations in Europe. This is the second microRNA licensing agreement
 for Rosetta since May, when the company signed a licensing agreement with
 Rockefeller University, and is part of a broader strategy to expand the
 company's product development capabilities. Rosetta Genomics microRNA
 patent portfolio already covers hundreds of human microRNA sequences.
     Rosetta Genomics is a leader in the development of microRNA-based
 diagnostics and therapeutics. The company focus is the rapidly evolving
 genomic field of microRNA. This agreement is expected to accelerate the
 company's product development timeline and expand its research capabilities
 by broadening Rosetta's microRNA portfolio. With this new agreement,
 Rosetta Genomics is now strategically positioned to target a broad range of
 product development opportunities in the diagnostics microRNA field.
     The licensed microRNAs sequences will be added to Rosetta Genomics
 microRNA database, providing the company with additional biomarker
 candidates for its diagnostic development programs. Under the terms of the
 agreement, Rosetta Genomics will be able to use these microRNAs to advance
 multiple research and development programs targeting new microRNA-based
 diagnostic tools for a variety of diseases.
     Rosetta Genomics has developed proprietary discovery process that has
 led to the discovery of hundreds of microRNAs of various species. This
 agreement positions Rosetta Genomics to pursue research and development
 based on a large number of microRNAs genes which the company believes exist
 in the human genome. Under the terms of the agreement, Rosetta Genomics
 will pay an initiation fee, as well as maintenance fees and royalties.
     About microRNAs
     MicroRNAs (miRNAs) are recently discovered, naturally occurring small
 RNAs that act as protein regulators and have the potential to form the
 basis for a new class of diagnostics and therapeutics. Since many diseases
 are caused by the abnormal activity of proteins, the ability to selectively
 regulate protein activity through microRNAs could provide the means to
 treat a wide range of human diseases. In addition, microRNAs have been
 shown to have different expression levels in certain diseased versus normal
 tissues. As a result, these differences potentially provide for a novel
 diagnostic strategy for many diseases. MicroRNAs are thought to play a key
 role in the differentiation of cells into specific cell types performing
 various functions in the body.
     About Max Planck Society / Garching Innovation
     Founded in 1948 as successor of the Kaiser Wilhelm Society, the Max
 Planck Society for the Advancement of Science is an independent, non-profit
 scientific research organization. Max Planck Society maintains almost 80
 research institutes, the majority of which are in Germany. The research
 institutes focus on natural sciences, life sciences, social sciences, and
 the humanities. The Max Planck Society is particularly active in new and
 innovative research areas that are outside the scope of German
 universities. Max Planck Society has produced 16 Nobel laureates since its
 foundation.
     Garching Innovation GmbH, a 100% subsidiary of Max Planck Society, acts
 as its technology transfer agency. Garching Innovation is responsible for
 the commercialization of intellectual property created within the research
 institutes of Max Planck Society by granting licenses to the industry.
     For more information, please visit www.mpg.de and
 www.garching-innovation.de.
     About Rosetta Genomics
     Rosetta Genomics is a leader in the development of microRNA-based
 diagnostics and therapeutics. Founded in 2000, the company's integrative
 research platform combining bioinformatics and state-of-the-art laboratory
 processes has led to the discovery of hundreds of biologically validated
 novel human microRNAs. Building on its strong IP position and strategic
 alliances with leading biotechnology companies, Rosetta Genomics is working
 to develop a full range of diagnostic and therapeutic products based on
 microRNAs. The company's primary focus is in the development of
 microRNA-based products to diagnose and treat different forms of cancer and
 infectious diseases.
     For more information, please visit: www.rosettagenomics.com
 
     Contact:
     VP of Marketing & Communications
     Odelia Goldfarb
     +972-8-948-4780
     odelia_go@RosettaGenomics.com
 
 

SOURCE Rosetta Genomics Ltd

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.